HIV treatment: latest news

HIV treatment resources

HIV treatment features

HIV treatment in your own words

HIV treatment news from aidsmap

More news

HIV treatment news selected from other sources

  • Déjà Vu – Claims of HIV Cures and Re-Treading Old Ground

    A few days ago while in Abuja, I was surprised to hear the news presenter announce that a Federal High Court had “lifted the ban” on Dr Abalaka’s “vaccine” against HIV. I was struck by a number of things – an abiding discomfort at the quality of reporting on science and health matters in the Nigerian media; a sense of guilt that, in failing to tell our stories, younger Nigerians are at risk of repeating missteps of the past; and a fear that many, misled by the news item, may put their lives at risk.

    28 January 2015 | Nigeria Health Watch
  • Why scientific AIDS explanations struggle in townships

    HIV/AIDS educators often seem to enjoy raising an eyebrow at outlandish beliefs over the disease. But in doing so they fail to realise that the joke is on them – these ideas continue to hold sway despite their best efforts.

    26 January 2015 | Africa Check
  • Bill Gates Predicts Two Miracles for AIDS Relief by 2030

    Bill Gates said he expects a pair of advances by 2030 that will eliminate most of the damage from AIDS. Improved treatment and the development of a vaccine to prevent new infections are the “two miracles” needed to help turn the tide, the billionaire said Friday at the World Economic Forum in Davos, Switzerland.

    26 January 2015 | Bloomberg
  • Merck (MRK) Receives Positive CHMP Opinion for Dutrebis as HIV 1 Treatment

    On 22 January 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Dutrebis, 150 mg lamivudine/300 mg raltegravir, film-coated tablet intended for the treatment of human immunodeficiency virus (HIV 1) infection in adults, adolescents, and children.

    26 January 2015 | Street Insider
  • Low CD4 count, suboptimal HIV treatment linked to higher anal cancer risk

    People with HIV who experienced extensive immune deficiency or who used early antiretroviral drugs before the advent of combination highly-active antiretroviral therapy (HAART) in the mid-90s may be at greater risk for developing anal cancer, according to a retrospective analysis published in the January 28 edition of AIDS.

    23 January 2015 | HIVandHepatitis.com
  • Exploring possible treatment options after virological failure with raltegravir

    In general, the integrase ihibitors raltegravir and dolutegravir have potent anti-HIV activity and have relatively few interactions with other drugs. However in clinical trials of raltegravir, strains of HIV that can resist raltegravir have emerged in up to 60% of heavily treatment-experienced people, and up to 8% of participants who have never taken HIV drugs before. A study in France of patients who had virologial failure to HIV therapy while taking raltegravir has found that 61% had HIV that was still susceptible to all integrase inhibitors. In cases where HIV was resistant to raltegravir, 14% were also resistant to dolutegravir.

    21 January 2015 | CATIE
  • Dramatic decline in risk for heart attacks among HIV-positive Kaiser Permanente members

    Previously reported increased risk of heart attacks among HIV-positive individuals has been largely reversed in recent years for Kaiser Permanente's California patients, according to a study published in the current online issue of Clinical Infectious Diseases. The adjusted risk ratio for heart attacks among HIV-positive study participants went from an 80 percent increased risk in 1996 to no increased risk in 2010-2011. Reported first on Aidsmap at http://www.aidsmap.com/Heart-attack-risk-in-people-with-HIV-may-be-falling-but-not-in-women/page/2834402/ .

    19 January 2015 | Eurekalert
  • Dolutegravir and Truimeq approved in England: London guidelines updated

    On 14 January 2015, NHS England published the long awaited policy on dolutegravir and the fixed dose combination (FDC) of dolutegravir/abacavir/3TC (Triumeq). The London prescribing guidelines for first-line therapy have also been updated to include dolutegravir and Triumeq.

    14 January 2015 | HIV i-Base
  • Dolutegravir/abacavir/lamivudine: considerable added benefit for treatment-naive adults with HIV

    Since September 2014, the fixed-dose combination of dolutegravir/abacavir/lamivudine (trade name Triumeq) has been approved for human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age. The Institute for Quality and Efficiency in Health Care (IQWiG), which had already assessed a dossier on dolutegravir in spring 2014, now examined in another dossier assessment whether the drug combination also offers an added benefit over the appropriate comparator therapy.

    12 January 2015 | The Institute for Quality and Efficiency in Health Care
  • I Am the Berlin Patient: A Personal Reflection

    My name is Timothy Ray Brown and I am the first person in the world to be cured of HIV.

    08 January 2015 | AIDS Research and Human Retroviruses
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.